Patients who have radiation therapy to the chest region often receive an unavoidable dose to the heart and, even small doses can increase the risk of cardiac disease in the future.1
It is this, in combination with cardiac toxicity from chemotherapy 2and shared risk factors between development of cancer and heart disease, that makes our patients vulnerable.
GenesisCare Foundation’s CAC Study, led by Doctors Yvonne Zissiadis and Nina Stewart, will identify whether the coronary artery calcium score, identified on thoracic radiation therapy planning CT scans, can be used and actioned to identify patients at high risk of cardiac events.
1 Ell P, et al. Curr Treat Ops Oncol. 2021; 10;22(8):70.
2 Jain D & Aronow W. Hosp Pract. 2019; 47(1):6-15.